Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Dementia01:30

Dementia

687
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
687
Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renewed mandate for Schools of Public Health: a call to action.

BMJ public health·2026
Same author

An exploration of demographic and conceptual factors related to attitudes towards dementia.

BMC geriatrics·2026
Same author

A qualitative study of the impact of the World Health Organisation QualityRights human rights and mental health Training on changing attitudes to mental health and human rights in Ghana.

Frontiers in health services·2026
Same author

The Nottingham consensus on dementia risk reduction policy: recommendations from a modified Delphi process.

Nature reviews. Neurology·2026
Same author

Impact of Music Interventions on Depression in Care Home Residents with Dementia: UK Results from Music Interventions for Depression and Dementia in Elderly Care RCT.

Geriatrics (Basel, Switzerland)·2025
Same author

Call to action: building a better future together, powered by evidence, guided by collective impact.

The Cochrane database of systematic reviews·2025
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
Same journal

Preconception and first-trimester metformin for improving pregnancy outcomes in women with polycystic ovary syndrome.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
05:54

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials

Published on: May 10, 2024

2.4K

Aromatherapy for dementia.

Lene Thorgrimsen Forrester1, Nicola Maayan, Martin Orrell

  • 1Department of Anaesthesia, NHS Grampian, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Aberdeenshire, UK, AB25 2ZN.

The Cochrane Database of Systematic Reviews
|February 27, 2014
PubMed
Summary
This summary is machine-generated.

Aromatherapy shows mixed results for dementia symptom management. While one study found benefits in agitation and behavioral symptoms, others showed no significant difference, indicating more research is needed.

Related Experiment Videos

Last Updated: May 2, 2026

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
05:54

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials

Published on: May 10, 2024

2.4K

Area of Science:

  • Gerontology
  • Neuroscience
  • Complementary Medicine

Background:

  • Complementary therapies, including aromatherapy, are gaining interest in dementia care.
  • Conventional treatments for dementia have limitations, including short-term efficacy and side effects.
  • Aromatherapy is explored for managing behavioral and psychological symptoms in dementia.

Purpose of the Study:

  • To evaluate the effectiveness of aromatherapy as an intervention for individuals with dementia.

Main Methods:

  • A systematic review of randomized controlled trials was conducted using the ALOIS database.
  • Searches included terms like 'aromatherapy,' 'essential oils,' and 'complementary therapies.'
  • Seven studies with 428 participants were included, with data analysis varying by study.

Main Results:

  • One trial (Ballard 2002) indicated significant reductions in agitation and behavioral symptoms with aromatherapy.
  • Another trial (Burns 2011) found no significant differences in agitation, behavioral symptoms, daily activities, or quality of life.
  • No significant differences in adverse effects were observed between aromatherapy and placebo groups.

Conclusions:

  • The current evidence on the benefits of aromatherapy for dementia is inconclusive.
  • Methodological limitations in existing studies necessitate more high-quality, large-scale randomized controlled trials.
  • Further research should address intervention comparability and outcome variations across dementia types.